Drug Discovery World Podcast: The unmet critical need for concussion drug therapies

The CEO of Oxeia,  Dr. Michael Wyand,  talks with Drug Discovery World’s multimedia editor, Megan Thomas, about  the unmet critical need for effective concussion therapies, Oxeia’s Phase 2a clinical trials, the challenges facing Oxeia as the company gears up for full-scale Phase 2 trials and the potential market for concussion drugs

Read more

Next
Next

Drug Discovery World: Neuroscience: Advances in research and opportunities ahead